Clinical Trial Update: Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating whether levocarnitine can reduce erythropoiesis-stimulating agent (ESA) requirements in hemodialysis patients with renal anemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• LEVOCARNITINE (levocarnitine)

Snippet

Sponsor: Shaikh Zayed Hospital, Lahore | Conditions: Anemia, Kidney Failure | Phase 4 | Status: NOT_YET_RECRUITING